Management of exit-site infections during continuous ambulatory peritoneal dialysis.
D002408:Catheters, Indwelling / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000008:administration & dosage; D005436:Floxacillin / Q000008:administration & dosage; D006801:Humans; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D011446:Prospective Studies; D012189:Retrospective Studies; D012293:Rifampin / Q000008:administration & dosage; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology
D005436:Floxacillin; D004917:Erythromycin; D012293:Rifampin